Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PULSE BIOSCIENCES, INC.PLSE · Entity 1151 | Chief Commercial Officer | February 18, 2026 | February 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PULSE BIOSCIENCES, INC.
Report date February 18, 2026 · Filed February 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 43,298 |
Ending reported balance
After 2026-02-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-18 · Exercise / conversion · Acquired 5,000 · Balance 48,298 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025. Row 2 · 2026-02-18 · Sale · Disposed 5,000 · Balance 43,298 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025. F2: The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $22.40 to $24.40 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.53 · Expires 2032-09-23 | Direct | 300,000 |
Reported balance
After 2026-02-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-18 · Exercise / conversion · Disposed 5,000 · Balance 300,000 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025. F3: Options granted on September 23, 2022, to acquire up to 450,000 shares of Common Stock, in connection with reporting person's promotion, with 25% vesting on each anniversary of grant, pursuant to the terms of an amendment to reporting person's Employment Agreement dated February 9, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025.
F2: The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $22.40 to $24.40 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range.
F3: Options granted on September 23, 2022, to acquire up to 450,000 shares of Common Stock, in connection with reporting person's promotion, with 25% vesting on each anniversary of grant, pursuant to the terms of an amendment to reporting person's Employment Agreement dated February 9, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2026 Filed Feb 24, 2026 01:55 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001437749-26-005144 · rdgdoc.xml · derivative · entry 3 Danahy Kevin Patrick · CIK 0001913245 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 5,000 shares Expires 2032-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025. F3 · derivative.exercise_date: Options granted on September 23, 2022, to acquire up to 450,000 shares of Common Stock, in connection with reporting person's promotion, with 25% vesting on each anniversary of grant, pursuant to the terms of an amendment to reporting person's Employment Agreement dated February 9, 2022. Read SEC document |
| February 18, 2026 Filed Feb 24, 2026 01:55 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | SaleCommon Stock | 5,000 | $23.64 | $118,200.00 |
DisclosureSEC source: 0001437749-26-005144 · rdgdoc.xml · nonDerivative · entry 2 Danahy Kevin Patrick · CIK 0001913245 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,298 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025. F2 · price: The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $22.40 to $24.40 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 18, 2026 Filed Feb 24, 2026 01:55 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionCommon Stock | 5,000 | $1.53 | $7,650.00 |
DisclosureSEC source: 0001437749-26-005144 · rdgdoc.xml · nonDerivative · entry 1 Danahy Kevin Patrick · CIK 0001913245 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 01:47 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001437749-26-004438 · rdgdoc.xml · derivative · entry 9 Danahy Kevin Patrick · CIK 0001913245 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 305,000 Underlying: Common Stock · 20,000 shares Expires 2032-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025. F5 · derivative.exercise_date: Options granted on September 23, 2022, to acquire up to 450,000 shares of Common Stock, in connection with reporting person's promotion, with 25% vesting on each anniversary of grant, pursuant to the terms of an amendment to reporting person's Employment Agreement dated February 9, 2022. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 01:47 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | SaleCommon Stock | 20,000 | $23.63 | $472,600.00 |
DisclosureSEC source: 0001437749-26-004438 · rdgdoc.xml · nonDerivative · entry 6 Danahy Kevin Patrick · CIK 0001913245 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,298 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025. F4 · price: The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $22.98 to $24.99 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 01:47 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionCommon Stock | 20,000 | $1.53 | $30,600.00 |
DisclosureSEC source: 0001437749-26-004438 · rdgdoc.xml · nonDerivative · entry 5 Danahy Kevin Patrick · CIK 0001913245 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 01:47 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001437749-26-004438 · rdgdoc.xml · derivative · entry 8 Danahy Kevin Patrick · CIK 0001913245 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 325,000 Underlying: Common Stock · 20,000 shares Expires 2032-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025. F5 · derivative.exercise_date: Options granted on September 23, 2022, to acquire up to 450,000 shares of Common Stock, in connection with reporting person's promotion, with 25% vesting on each anniversary of grant, pursuant to the terms of an amendment to reporting person's Employment Agreement dated February 9, 2022. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 01:47 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | SaleCommon Stock | 20,000 | $23.53 | $470,600.00 |
DisclosureSEC source: 0001437749-26-004438 · rdgdoc.xml · nonDerivative · entry 4 Danahy Kevin Patrick · CIK 0001913245 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,298 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025. F3 · price: The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $23.00 to $25.00 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 01:47 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionCommon Stock | 20,000 | $1.53 | $30,600.00 |
DisclosureSEC source: 0001437749-26-004438 · rdgdoc.xml · nonDerivative · entry 3 Danahy Kevin Patrick · CIK 0001913245 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 01:47 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001437749-26-004438 · rdgdoc.xml · derivative · entry 7 Danahy Kevin Patrick · CIK 0001913245 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 345,000 Underlying: Common Stock · 20,000 shares Expires 2032-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025. F5 · derivative.exercise_date: Options granted on September 23, 2022, to acquire up to 450,000 shares of Common Stock, in connection with reporting person's promotion, with 25% vesting on each anniversary of grant, pursuant to the terms of an amendment to reporting person's Employment Agreement dated February 9, 2022. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 01:47 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | SaleCommon Stock | 20,000 | $23.37 | $467,400.00 |
DisclosureSEC source: 0001437749-26-004438 · rdgdoc.xml · nonDerivative · entry 2 Danahy Kevin Patrick · CIK 0001913245 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,298 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025. F2 · price: The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $22.81 to $26.00 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 01:47 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionCommon Stock | 20,000 | $1.53 | $30,600.00 |
DisclosureSEC source: 0001437749-26-004438 · rdgdoc.xml · nonDerivative · entry 1 Danahy Kevin Patrick · CIK 0001913245 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025. Read SEC document |
| February 11, 2026 Filed Feb 12, 2026 00:46 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001437749-26-003840 · rdgdoc.xml · derivative · entry 9 Danahy Kevin Patrick · CIK 0001913245 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 365,000 Underlying: Common Stock · 20,000 shares Expires 2032-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025. F5 · derivative.exercise_date: Options granted on September 23, 2022, to acquire up to 450,000 shares of Common Stock, in connection with reporting person's promotion, with 25% vesting on each anniversary of grant, pursuant to the terms of an amendment to reporting person's Employment Agreement dated February 9, 2022. Read SEC document |
| February 11, 2026 Filed Feb 12, 2026 00:46 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | SaleCommon Stock | 20,000 | $25.20 | $504,000.00 |
DisclosureSEC source: 0001437749-26-003840 · rdgdoc.xml · nonDerivative · entry 6 Danahy Kevin Patrick · CIK 0001913245 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,298 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025. F4 · price: The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $23.36 to $26.36 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 11, 2026 Filed Feb 12, 2026 00:46 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionCommon Stock | 20,000 | $1.53 | $30,600.00 |
DisclosureSEC source: 0001437749-26-003840 · rdgdoc.xml · nonDerivative · entry 5 Danahy Kevin Patrick · CIK 0001913245 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 00:46 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001437749-26-003840 · rdgdoc.xml · derivative · entry 8 Danahy Kevin Patrick · CIK 0001913245 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 385,000 Underlying: Common Stock · 20,000 shares Expires 2032-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025. F5 · derivative.exercise_date: Options granted on September 23, 2022, to acquire up to 450,000 shares of Common Stock, in connection with reporting person's promotion, with 25% vesting on each anniversary of grant, pursuant to the terms of an amendment to reporting person's Employment Agreement dated February 9, 2022. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 00:46 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | SaleCommon Stock | 20,000 | $23.52 | $470,400.00 |
DisclosureSEC source: 0001437749-26-003840 · rdgdoc.xml · nonDerivative · entry 4 Danahy Kevin Patrick · CIK 0001913245 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,298 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025. F3 · price: The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $23.00 to $26.08 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 00:46 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionCommon Stock | 20,000 | $1.53 | $30,600.00 |
DisclosureSEC source: 0001437749-26-003840 · rdgdoc.xml · nonDerivative · entry 3 Danahy Kevin Patrick · CIK 0001913245 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025. Read SEC document |
| February 09, 2026 Filed Feb 12, 2026 00:46 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001437749-26-003840 · rdgdoc.xml · derivative · entry 7 Danahy Kevin Patrick · CIK 0001913245 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 405,000 Underlying: Common Stock · 20,000 shares Expires 2032-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025. F5 · derivative.exercise_date: Options granted on September 23, 2022, to acquire up to 450,000 shares of Common Stock, in connection with reporting person's promotion, with 25% vesting on each anniversary of grant, pursuant to the terms of an amendment to reporting person's Employment Agreement dated February 9, 2022. Read SEC document |
| February 09, 2026 Filed Feb 12, 2026 00:46 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | SaleCommon Stock | 20,000 | $21.45 | $429,000.00 |
DisclosureSEC source: 0001437749-26-003840 · rdgdoc.xml · nonDerivative · entry 2 Danahy Kevin Patrick · CIK 0001913245 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,298 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025. F2 · price: The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $21.00 to $23.22 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 09, 2026 Filed Feb 12, 2026 00:46 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionCommon Stock | 20,000 | $1.53 | $30,600.00 |
DisclosureSEC source: 0001437749-26-003840 · rdgdoc.xml · nonDerivative · entry 1 Danahy Kevin Patrick · CIK 0001913245 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025. Read SEC document |
| October 02, 2025 Filed Oct 7, 2025 23:18 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionStock Option (right to buy) · Derivative | 4,600 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001437749-25-030665 · rdgdoc.xml · derivative · entry 3 Danahy Kevin Patrick · CIK 0001913245 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 425,000 Underlying: Common Stock · 4,600 shares Expires 2032-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025. F3 · derivative.exercise_date: Options granted on September 23, 2022, to acquire up to 450,000 shares of Common Stock, in connection with reporting person's promotion, with 25% vesting on each anniversary of grant, pursuant to the terms of an amendment to reporting person's Employment Agreement dated February 9, 2022. Read SEC document |
| October 02, 2025 Filed Oct 7, 2025 23:18 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | SaleCommon Stock | 4,600 | $18.53 | $85,238.00 |
DisclosureSEC source: 0001437749-25-030665 · rdgdoc.xml · nonDerivative · entry 2 Danahy Kevin Patrick · CIK 0001913245 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,298 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025. F2 · price: The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $18.48 to $18.65 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 02, 2025 Filed Oct 7, 2025 23:18 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionCommon Stock | 4,600 | $1.53 | $7,038.00 |
DisclosureSEC source: 0001437749-25-030665 · rdgdoc.xml · nonDerivative · entry 1 Danahy Kevin Patrick · CIK 0001913245 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,898 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025. Read SEC document |
| September 19, 2025 Filed Sep 23, 2025 01:24 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionStock Option (right to buy) · Derivative | 400 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001437749-25-029646 · rdgdoc.xml · derivative · entry 6 Danahy Kevin Patrick · CIK 0001913245 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 429,600 Underlying: Common Stock · 400 shares Expires 2032-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025. F3 · derivative.exercise_date: Options granted on September 23, 2022, to acquire up to 450,000 shares of Common Stock, in connection with reporting person's promotion, with 25% vesting on each anniversary of grant, pursuant to the terms of an amendment to reporting person's Employment Agreement dated February 9, 2022. Read SEC document |
| September 19, 2025 Filed Sep 23, 2025 01:24 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | SaleCommon Stock | 400 | $18.48 | $7,392.00 |
DisclosureSEC source: 0001437749-25-029646 · rdgdoc.xml · nonDerivative · entry 4 Danahy Kevin Patrick · CIK 0001913245 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,298 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025. Read SEC document |
| September 19, 2025 Filed Sep 23, 2025 01:24 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionCommon Stock | 400 | $1.53 | $612.00 |
DisclosureSEC source: 0001437749-25-029646 · rdgdoc.xml · nonDerivative · entry 3 Danahy Kevin Patrick · CIK 0001913245 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,698 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025. Read SEC document |
| September 18, 2025 Filed Sep 23, 2025 01:24 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001437749-25-029646 · rdgdoc.xml · derivative · entry 5 Danahy Kevin Patrick · CIK 0001913245 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 430,000 Underlying: Common Stock · 20,000 shares Expires 2032-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025. F3 · derivative.exercise_date: Options granted on September 23, 2022, to acquire up to 450,000 shares of Common Stock, in connection with reporting person's promotion, with 25% vesting on each anniversary of grant, pursuant to the terms of an amendment to reporting person's Employment Agreement dated February 9, 2022. Read SEC document |
| September 18, 2025 Filed Sep 23, 2025 01:24 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | SaleCommon Stock | 20,000 | $18.49 | $369,800.00 |
DisclosureSEC source: 0001437749-25-029646 · rdgdoc.xml · nonDerivative · entry 2 Danahy Kevin Patrick · CIK 0001913245 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,298 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025. F2 · price: The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $18.48 to $19.48 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 18, 2025 Filed Sep 23, 2025 01:24 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionCommon Stock | 20,000 | $1.53 | $30,600.00 |
DisclosureSEC source: 0001437749-25-029646 · rdgdoc.xml · nonDerivative · entry 1 Danahy Kevin Patrick · CIK 0001913245 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025. Read SEC document |
| July 03, 2024 Filed Jul 9, 2024 13:12 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseWarrant (right to buy) · Derivative | 325 | Not disclosed Strike: $11.00 | Not disclosed |
DisclosureSEC source: 0001437749-24-022356 · rdgdoc.xml · derivative · entry 3 Danahy Kevin Patrick · CIK 0001913245 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 325 Underlying: Common Stock · 325 shares Expires 2029-07-03 F1 · kind: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F1 · price: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F2 · price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $10.00 per unit, with each unit consisting of one share of common stock and two warrants each to purchase one half share of common stock at an exercise price of $11.00 per whole share. The warrants differ only in their redemption provisions. Read SEC document |
| July 03, 2024 Filed Jul 9, 2024 13:12 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseWarrant (right to buy) · Derivative | 325 | Not disclosed Strike: $11.00 | Not disclosed |
DisclosureSEC source: 0001437749-24-022356 · rdgdoc.xml · derivative · entry 2 Danahy Kevin Patrick · CIK 0001913245 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 325 Underlying: Common Stock · 325 shares Expires 2029-07-03 F1 · kind: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F1 · price: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F2 · price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $10.00 per unit, with each unit consisting of one share of common stock and two warrants each to purchase one half share of common stock at an exercise price of $11.00 per whole share. The warrants differ only in their redemption provisions. Read SEC document |
| July 03, 2024 Filed Jul 9, 2024 13:12 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherCommon Stock | 650 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-022356 · rdgdoc.xml · nonDerivative · entry 1 Danahy Kevin Patrick · CIK 0001913245 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,537 F1 · kind: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F2 · price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $10.00 per unit, with each unit consisting of one share of common stock and two warrants each to purchase one half share of common stock at an exercise price of $11.00 per whole share. The warrants differ only in their redemption provisions. Read SEC document |
| November 16, 2023 Filed Nov 17, 2023 14:11 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 12 | $6.50 | $78.00 |
DisclosureSEC source: 0001437749-23-032410 · rdgdoc.xml · nonDerivative · entry 3 Danahy Kevin Patrick · CIK 0001913245 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,887 Read SEC document |
| November 16, 2023 Filed Nov 17, 2023 14:11 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 600 | $6.51 | $3,906.00 |
DisclosureSEC source: 0001437749-23-032410 · rdgdoc.xml · nonDerivative · entry 2 Danahy Kevin Patrick · CIK 0001913245 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,875 Read SEC document |
| November 16, 2023 Filed Nov 17, 2023 14:11 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 4,781 | $6.52 | $31,171.64 |
DisclosureSEC source: 0001437749-23-032410 · rdgdoc.xml · nonDerivative · entry 1 Danahy Kevin Patrick · CIK 0001913245 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,275 Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 21:41 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 460,000 | $0.00 Strike: $4.38 | $0.00 |
DisclosureSEC source: 0001437749-23-030250 · rdgdoc.xml · derivative · entry 3 Danahy Kevin Patrick · CIK 0001913245 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 460,000 Underlying: Common Stock · 460,000 shares Expires 2033-11-01 F3 · derivative.exercise_date: 100% vesting upon the earlier of (i) the six (6) year anniversary of the grant date, and (ii) the 1-year anniversary of a Company change of control. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 21:41 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherStock Option (right to buy) · Derivative | 130,000 | $0.00 Strike: $3.96 | $0.00 |
DisclosureSEC source: 0001437749-23-030250 · rdgdoc.xml · derivative · entry 2 Danahy Kevin Patrick · CIK 0001913245 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 130,000 shares Expires 2033-10-23 F2 · kind: Reporting Person was erroneously granted an option to acquire 130,000 shares on October 23, 2023, which option was cancelled by mutual agreement on November 1, 2023. F1 · derivative.exercise_date: The shares will vest in four equal annual installments on each of the first four annual anniversaries of the grant date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| October 23, 2023 Filed Nov 3, 2023 21:41 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 130,000 | $0.00 Strike: $3.96 | $0.00 |
DisclosureSEC source: 0001437749-23-030250 · rdgdoc.xml · derivative · entry 1 Danahy Kevin Patrick · CIK 0001913245 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2033-10-23 F1 · derivative.exercise_date: The shares will vest in four equal annual installments on each of the first four annual anniversaries of the grant date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| July 12, 2023 Filed Jul 15, 2023 00:29 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 200,000 | Not disclosed Strike: $7.08 | Not disclosed |
DisclosureSEC source: 0001437749-23-019993 · rdgdoc.xml · derivative · entry 1 Danahy Kevin Patrick · CIK 0001913245 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-07-12 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on July 12, 2023 under the Issuer's 2017 Equity Incentive Plan. The shares subject to the option are subject to two tranches of performance-based vesting criteria tied to Issuer's market capitalization, with no vesting until the Issuer's market capitalization exceeds $4 billion, in both cases, subject to the Reporting Person's continued service through each vesting milestone. Read SEC document |
| April 29, 2023 Filed May 3, 2023 01:45 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 500,000 | Not disclosed Strike: $6.44 | Not disclosed |
DisclosureSEC source: 0001437749-23-012180 · rdgdoc.xml · derivative · entry 1 Danahy Kevin Patrick · CIK 0001913245 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2033-04-29 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on April 29, 2023 under the Issuer's 2017 Equity Incentive Plan. The shares subject to the option are subject to four tranches of performance-based vesting criteria tied to Issuer's market capitalization, with no vesting until the Issuer's market capitalization exceeds $1 billion, in all cases, subject to the Reporting Person's continued service through each vesting milestone. Read SEC document |
| March 17, 2023 Filed Mar 24, 2023 20:31 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $6.41 | $0.00 |
DisclosureSEC source: 0001437749-23-007824 · rdgdoc.xml · derivative · entry 1 Danahy Kevin Patrick · CIK 0001913245 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-02-14 F1 · derivative.underlying_shares: On February 14, 2022, the reporting person was granted an option to purchase 150,000 shares of the Issuer's common stock. The option vests upon the achievement of performance objectives, with vesting targets of 25% vesting per year upon achievement of said objectives established by the Issuer's Compensation Committee, subject to the reporting person's continued service through each vesting date. The performance objectives for 2022 were met, resulting in the vesting of the option as to 25,000 shares. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 20:35 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 6,500 | $2.30 | $14,950.00 |
DisclosureSEC source: 0001839882-22-022698 · danahy-form4_093022.xml · nonDerivative · entry 1 Danahy Kevin Patrick · CIK 0001913245 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 F1 · price: This purchase price represents the weighted average purchase price of the shares purchased on September 30, 2022, ranging from $2.28 to $2.31 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| September 23, 2022 Filed Sep 27, 2022 21:46 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 450,000 | Not disclosed Strike: $1.53 | Not disclosed |
DisclosureSEC source: 0001387131-22-010043 · danahy-form4_092722.xml · derivative · entry 1 Danahy Kevin Patrick · CIK 0001913245 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2032-09-23 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on September 23, 2022 under the Issuer's 2017 Equity Incentive Plan and pursuant to an amendment to the Reporting Person's employment agreement. The shares will vest in four equal annual installments on each of the first four annual anniversaries of the grant date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| February 14, 2022 Filed Mar 22, 2022 20:11 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 300,000 | Not disclosed Strike: $6.41 | Not disclosed |
DisclosureSEC source: 0001104659-22-036559 · tm2210083-2_4seq1.xml · derivative · entry 1 Danahy Kevin Patrick · CIK 0001913245 · Chief Commercial Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2032-02-14 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on February 14, 2022 under the Issuer's 2017 Inducement Equity Incentive Plan. The shares subject to the option are subject to a mix of time-based and performance-based vesting criteria. 200,000 shares will vest in equal annual installments over the following four years on the anniversary of the grant date and 100,000 shares will vest in two equal annual installments on the third and fourth anniversaries of the grant date, in all cases, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.